Be Biopharma
Be Biopharma is developing a proprietary class of engineered B cells as medicines in applications beyond cytotoxicity.
3
Funding Rounds
$264.0m
Money raised
Funding
Funding series
Funding Series Analysis
The company Be Biopharma has raised a total of $264m in funding over 3 rounds.
Key Insights:
- Be Biopharma October 2024 Venture - Series Unknown Funding Round: $82m
- Be Biopharma Series B round, April 2022: $130m
- Be Biopharma Series A round, October 2020: $52m
Be Biopharma October 2024 Venture - Series Unknown Funding Round
$82m
Be Biopharma Series B round, April 2022
$130m
Be Biopharma Series A round, October 2020
$52m
Industries
Be Biopharma is active in the following industries:
- Technology
- Biotechnology
- Health technology